Search results
Results from the WOW.Com Content Network
An epinephrine autoinjector (or adrenaline autoinjector, also known by the trademark EpiPen) is a medical device for injecting a measured dose or doses of epinephrine (adrenaline) by means of autoinjector technology. It is most often used for the treatment of anaphylaxis. The first epinephrine autoinjector was brought to market in 1983.
The practice of intracardiac injection originated in the 1800s. It was commonly performed during the 1960s, as it was considered the fastest way to get medication to the heart. The practice began declining during the 1970s as more reliable delivery methods (i.e., intravenous , endotracheal , and intraosseous ) came into use.
Epinephrine, also known as adrenaline, is a medication and hormone. [10] [11] As a medication, it is used to treat several conditions, including anaphylaxis, cardiac arrest, asthma, and superficial bleeding. [8] Inhaled epinephrine may be used to improve the symptoms of croup. [12] It may also be used for asthma when other treatments are not ...
The AOL.com video experience serves up the best video content from AOL and around the web, curating informative and entertaining snackable videos.
Generic drugmaker Sandoz announced plans Thursday to start selling an alternative to the EpiPen in the U.S. early next year.
Some medications are formulated as injector pens to quicken the onset of action of the medication. This includes epinephrine, which when used to treat anaphylaxis must work as soon as possible. [19] Contrary to most other injector pens, epinephrine injector pens are designed to administer the medication via intramuscular injection. [19]
An injection of Auvi-Q autoinjector. Another design has a shape and size of a smartphone which can be put into a pocket. This design also has a retractable needle and automated voice instructions to assist the users on how to correctly use the autoinjector. The "Auvi-Q" epinephrine autoinjector uses this design. [8]
Pfizer’s EpiPens may have set consumers back $600, but it’s now costing the drugmaker a whole lot more. Pfizer has agreed to pay $345 million to resolve claims by consumers who alleged they ...